Skip to content

Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients

Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04553835
Enrollment
60
Registered
2020-09-17
Start date
2020-08-31
Completion date
2022-12-31
Last updated
2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyskinesias, Parkinsonism, Psychosis, Schizophrenia

Brief summary

The purpose of this research is to examine effects of movement training with the aid of rhythmic auditory stimulation (RAS) on reducing severity of dyskinesia and bradykinesia in at-risk individuals and schizophrenia patients. The investigators hypothesize that training with the aid of RAS reduced severity of bradykinesia and dyskinesia in at-risk individuals as well as in schizophrenia patients.

Interventions

BEHAVIORALRhythmic auditory stimulation (RAS) for schizophrenia patients

A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday.

BEHAVIORALNo RAS for schizophrenia patients

The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.

BEHAVIORALRAS for at-risk individuals

A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day.

BEHAVIORALNo RAS for at-risk individuals

The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.

Sponsors

Dr WANG Shumei
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
13 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

For at-risk individuals: The inclusion criteria for at-risk individuals are: 1. A score of or above 9 in the Chinese version of the 16-item Prodromal Questionnaire (CPQ-16), or a score of or above 8.18 in the Chinese version of Community Assessment of Psychic Experiences with 15 items (CAPE-C15), or a score of or above 17 in Schizotypal Personality Questionnaire-Brief (SPQ-B); 2. A score of or above 22 in the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) to ensure that they can understand instructions; 3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory to ensure that they are right-handed. 4. The age ≥ 13 years. The inclusion criteria for healthy controls are: 1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B; 2. A score of or above 22 in MoCA; 3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory; 4. No first-degree family members having a diagnosis of mental illnesses. 5. The age ≥ 13 years. At-risk participants and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements. For schizophrenia patients: The inclusion criteria for schizophrenia patients are: 1. A diagnosis of schizophrenia without other psychiatric diseases; 2. Having stable psychotic symptoms; 3. A score of or above 22 in HK-MoCA; 4. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory. 5. The age ≥ 18 years. The inclusion criteria for healthy controls are: 1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B; 2. A score of or above 22 in MoCA; 3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory; 4. No first-degree family members having a diagnosis of mental illnesses. 5. The age ≥ 18 years. Patients and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements.

Design outcomes

Primary

MeasureTime frameDescription
Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)Within one week right before the 1st session of the interventionnormalized movement time (representing severity of parkinsonism). Unit: second/mm

Countries

Hong Kong

Contacts

Primary ContactShu-Mei Wang, PhD
shumei.wang@polyu.edu.hk852-27664197

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026